Thus, the controversies surrounding the gene expression of CYP19A1 in breast tumor studies and, to the best of our knowledge, the absence of studies analyzing the peripheral blood of women with recurrent breast cancer led to the design of this study. Here, CYP19A1 is linked to breast carcinoma.